Key facts
- This page summarizes SUMMER ROAD LLC's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2024, 16:43.
SUMMER ROAD LLC - 26 Feb 2024 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- OCUL
- Reported as of
- 26 Feb 2024
- Net transaction value
- +$7,000,000
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2024, 16:43:51 UTC
- Prior SEC filing
- 18 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard A. Silberberg, Chief Operating Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
SUMMER ROAD LLC filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 27 Feb 2024.
Change
- Previous filing in this sequence was filed on 18 Dec 2023.
- Current net transaction value: +$7,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCUL
transaction
Common Stock, $0.0001 par value per share
Purchase
- Transaction value
- $7,000,000
- Shares
- +930,851
- Change %
- +12%
- Price
- $7.52
- Shares after
- 8,591,401
- Date
- 26 Feb 2024
- Ownership
- By Family Client
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
SUMMER ROAD LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
These shares of Common Stock, $0.0001 par value per share (the "Common Stock"), were purchased by the Reporting Person at a price of $7.52 per share (the "Acquired Shares") through a private placement that closed on February 26, 2024 (the "Private Placement"), pursuant to a Securities Purchase Agreement, dated February 21, 2024, a copy of which was filed as Exhibit 10.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission (the "SEC") on February 22, 2024. In connection with the Private Placement, the Reporting Person also entered into a Registration Rights Agreement, dated February 21, 2024, a copy of which was filed as Exhibit 10.2 to the Issuer's Form 8-K filed with the SEC on February 22, 2024, pursuant to which the Issuer agreed to register for resale the Acquired Shares no later than 30 days following the closing of the Private Placement.
Footnote F2
Reporting Person is a family office of the same family under Investment Advisers Act of 1940 Rule 202(a)(11)(G)-1 (the "Family Office Rule"). Pursuant to investment management agreements ("IMAs") between itself and its "Family Clients" (as defined in the Family Office Rule), Reporting Person exercises voting and dispositive power with respect to the Common Stock, held by each of the Family Clients. The Reporting Person also reports beneficial ownership pursuant to Rule 13d-1 of the Securities Exchange Act of 1934, as amended, pursuant to a Schedule 13D previously filed with the SEC on May 19, 2020, as amended from time to time.
Footnote F3
Represents securities beneficially owned by Reporting Person through an IMA entered into with Family Clients. The securities acquired as to which this Form 4 is filed by Reporting Person are owned of record by Cap 1 LLC, a Family Client of Reporting Person ("Cap 1"). Cap 1 is owned over 90% by Crystal Fiduciary Company, LLC, as Trustee of the AR Irrevocable Trust. Reporting Person has no pecuniary interest in the securities beneficially owned by the Family Clients of Reporting Person.